🔗 Share this article WHO Raises Warning Over Acute Shortage of Obesity Jabs Fewer than a tenth of people that would benefit from weight-loss injections like Wegovy have access to them, warns the WHO as it releases its initial recommendations on the drugs. Given in excess of 1,000,000,000 individuals worldwide now obese, it is urging increased and just access to this class of drugs. Based on projections, over two billion could be living with obesity by 2030 unless action is taken. "The new guidelines recognises that excess weight is a long-term condition that can be addressed with thorough and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are major obstacles to universal access to the jabs that can aid individuals in losing considerable body mass, notes the organization. Skinny Jab Supply Crisis Even under the present most favorable outlook, the production of GLP-1 therapies would only suffice for about 100 million people – less than 10% of the global need, per the health organization. The guideline urges governments and firms to expand availability, via strategies including licensing agreements. A patent on the active ingredient – the main component of a leading brand – is set to lapse in multiple nations in 2026. The Way Obesity Drugs Operate The injections imitate a biological compound to delay gastric emptying, reduce hunger and enhance the sense of being full so individuals eat less. Individuals commonly see weight reduction after several weeks of beginning the weekly injections. Research suggests patients may regain a significant portion after a year of discontinuing the treatment, because their usual food cravings return. Being above a healthy weight raises your risk for experiencing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies. Excess weight impacts people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
Fewer than a tenth of people that would benefit from weight-loss injections like Wegovy have access to them, warns the WHO as it releases its initial recommendations on the drugs. Given in excess of 1,000,000,000 individuals worldwide now obese, it is urging increased and just access to this class of drugs. Based on projections, over two billion could be living with obesity by 2030 unless action is taken. "The new guidelines recognises that excess weight is a long-term condition that can be addressed with thorough and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are major obstacles to universal access to the jabs that can aid individuals in losing considerable body mass, notes the organization. Skinny Jab Supply Crisis Even under the present most favorable outlook, the production of GLP-1 therapies would only suffice for about 100 million people – less than 10% of the global need, per the health organization. The guideline urges governments and firms to expand availability, via strategies including licensing agreements. A patent on the active ingredient – the main component of a leading brand – is set to lapse in multiple nations in 2026. The Way Obesity Drugs Operate The injections imitate a biological compound to delay gastric emptying, reduce hunger and enhance the sense of being full so individuals eat less. Individuals commonly see weight reduction after several weeks of beginning the weekly injections. Research suggests patients may regain a significant portion after a year of discontinuing the treatment, because their usual food cravings return. Being above a healthy weight raises your risk for experiencing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies. Excess weight impacts people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.